Bank Julius Baer & Co. Ltd, Zurich Atea Pharmaceuticals, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	BUY	$4.35 - $6.17 $191 - $271	44 Added 1.6%	2,800 $13,000
Q3 2022 Nov 04, 2022	SELL	$5.49 - $8.79 $241 - $386	-44 Reduced 1.57%	2,756 $16,000
Q1 2022 May 09, 2022	BUY	$5.5 - $9.19 $15,400 - $25,732	2,800 New	2,800 $20,000
Q2 2021 Jul 23, 2021	SELL	$19.22 - $59.08 $1.49 Million - $4.59 Million	-77,652 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$41.42 - $88.44 $3.22 Million - $6.87 Million	77,652 New	77,652 $4.8 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.